Lunatocapitate Fusion Versus Four-corner Fusion for SNAC and SLAC Arthritis. (MIKA)

Lunatocapitate Fusion Versus Four-corner Fusion for SNAC and SLAC Arthritis. A Randomized Comparison.

Hypothesis: Lunate-capitate-fusion (LCF) results in comparable outcome (i.e. not worse) to four-corner-fusion (4CF) for Scaphoid Nonunion Advanced Collapse (SNAC) and Scapholunate Advanced Collapse (SLAC) arthritis regarding functional results (grip strength).

Design: Prospective randomised comparison. Inclusion criteria: SNAC or SLAC arthritis requiring a salvage procedure (grade 2-3).

Exclusion criteria: SNAC or SLAC arthritis grade 4 (panarthritis). Inability to co-operate with the follow-up protocol (language difficulties, severe psychiatric disorder or drug addiction).

Study Overview

• Status: Active, not recruiting
• Conditions: Wrist Arthritis
• Intervention / Treatment: Procedure: Lunate-Capitate Fusion (LCF); Procedure: Four Corner Fusion (4CF)

Detailed Description

Surgical method:

Patient will be operated in axially plexus with a dorsal approach through the 3d and 4th extensor tendon compartments. The wrist joint capsule will be opened with a Berger incision. After excision of the scaphoid and preparation of the articular surfaces to be fused, the bones will be fixated with k-wires. Bone autograft from the scaphoid, crista or radius will be used according to the surgeon's preference based on the condition of the fusion surfaces. The wrist be immobilized in a short arm plaster cast until the fusions are radiologically healed after10-12 weeks. The k-wires will be extracted in local anesthesia after another 2-6 weeks.

Sample size:

This study will have a power of 80% to show that the mean grip strength for LC fusion is as least as high as the mean for 4CF (non-inferiority). This assumes that the means for the LC fusion and the 4CF are equal (at 70% of the uninjured side) with a common within-group standard deviation of 14 (Salzman et al. 2015), that a difference of 10% or less is unimportant, that the sample size in the two groups will be 25 and 25, and the alpha (1 tailed) is set at 0,05.Formally, the null hypothesis is that the mean for lunocapitate fusion is 10% lower than the mean for 4CF, and that the study has power of 80,1% to reject this null. Equivalently, the likelihood is 80,1% that the 95% confidence interval for the mean difference will exclude a difference of 10% in favor of 4CF.

We aim to include 60 patients to cover for a certain loss to follow-up.

Assessment:

Patients will be assessed regarding range of motion and grip strength and complete the DASH and PRWE questionnaires before surgery (baseline) and 1 and 2 years postoperatively.

Radiology:

Plain anterior and lateral radiographs will be obtained 1 and 2 years postoperatively for purpose of the study. According to the standard treatment protocol, clinical and radiological healing assessment will be conducted 10-12 weeks postoperatively. Radiographs will be analyzed by a radiologist.

Complications will be recorded 1 and 2 years postoperatively.

Analyzes:

The Mann-Whitney and Chi-square tests will be used for non-parametric data (DASH, PRWE and presence of arthritis and complications). T-test will be used for numerical data (ROM, grip strength).

• Study Type: Interventional
• Enrollment (Actual): 64
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Sweden
  • Stockholm, Sweden
    • Dept of Handsurgery SÖS

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 14 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

- SNAC or SLAC arthritis grade 2-3

Exclusion Criteria:

• SNAC or SLAC arthritis grade 4
• Inability to cooperate with the follow-up protocol

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Lunate-Capitate Fusion (LCF); Operation with a Lunate-Capitate Fusion (LCF) for SLAC or SNAC arthritis.	Procedure: Lunate-Capitate Fusion (LCF); Operation with lunate-capitate-fusion (LCF)
Active Comparator: Four Corner Fusion (4CF); Operation with a Four Corner Fusion (4CF) for SLAC or SNAC arthritis	Procedure: Four Corner Fusion (4CF); Operation with four-corner-fusion (4CF)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Grip strength	Hand grip strength measured with Jamar dynamometer	1 year postoperatively

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
DASH score	Disability of the Arm, Hand and Shoulder (DASH) questionnaire	1 year postoperatively
PRWE score	Patient Rated Wrist Evaluation (PRWE)	1 year postoperatively
Range of motion (ROM)	Wrist ROM measured with a goniometer	1 year postoperatively
EQ5D (for analysis of health economy)	Quality of life questionnaire	1 year postoperatively
Complications	Infection, nonunion	1 year postoperatively
Progress of arthritis	Radiological signs of radiocarpal arthritis on CT scans	1 year postoperatively

Collaborators and Investigators

• Sponsor: Karolinska Institutet
• Collaborators: Skane University Hospital
• Investigators: Study Director: Maria Wilcke, MD, PhD, Stockholm, Sweden

Study record dates

Study Major Dates

• Study Start (Actual): September 1, 2017
• Primary Completion (Actual): April 30, 2023
• Study Completion (Estimated): April 30, 2027

Study Registration Dates

• First Submitted: August 21, 2017
• First Submitted That Met QC Criteria: October 16, 2017
• First Posted (Actual): October 20, 2017

Study Record Updates

• Last Update Posted (Estimated): September 8, 2025
• Last Update Submitted That Met QC Criteria: August 31, 2025
• Last Verified: August 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Joint Diseases; Musculoskeletal Diseases; Arthritis
• Other Study ID Numbers: MIKA1

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No